Human versus HIV: round 2 defeat in AIDS vaccine development

[1] Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D [J]. JOURNAL OF VIROLOGY, 2007, 81 (09) : 4654 - 4663

[2] Adenovirus vector-based vaccines for human immunodeficiency virus type 1 [J]. HUMAN GENE THERAPY, 2005, 16 (02) : 149 - 156

[3] AIDS research - Did Merck's failed HIV vaccine cause harm [J]. SCIENCE, 2007, 318 (5853) : 1048 - 1049

[4] Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2007, 45 (01) : 20 - 27

[5] Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction [J]. JOURNAL OF GENERAL VIROLOGY, 2007, 88 : 1 - 12

[6] *HVTN, 2007, HIV VACC TRIALS NET

[7] RESPIRATORY SYNCYTIAL VIRUS DISEASE IN INFANTS DESPITE PRIOR ADMINISTRATION OF ANTIGENIC INACTIVATED VACCINE [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 1969, 89 (04) : 422 - +

[8] The Cutter incident, 50 years later [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (14) : 1411 - 1412

[9] Immunogenicity in Macaques of the clinical product for a clade B DNA/MVA HIV vaccine:: Elicitation of IFN-γ, IL-2, and TNF-α coproducing CD4 and CD8 T cells [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2007, 23 (12) : 1555 - 1561

[10] Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity [J]. NATURE, 2002, 415 (6869) : 331 - 335

[1] Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D [J]. JOURNAL OF VIROLOGY, 2007, 81 (09) : 4654 - 4663

[2] Adenovirus vector-based vaccines for human immunodeficiency virus type 1 [J]. HUMAN GENE THERAPY, 2005, 16 (02) : 149 - 156

[3] AIDS research - Did Merck's failed HIV vaccine cause harm [J]. SCIENCE, 2007, 318 (5853) : 1048 - 1049

[4] Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2007, 45 (01) : 20 - 27

[5] Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction [J]. JOURNAL OF GENERAL VIROLOGY, 2007, 88 : 1 - 12

[6] *HVTN, 2007, HIV VACC TRIALS NET

[7] RESPIRATORY SYNCYTIAL VIRUS DISEASE IN INFANTS DESPITE PRIOR ADMINISTRATION OF ANTIGENIC INACTIVATED VACCINE [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 1969, 89 (04) : 422 - +

[8] The Cutter incident, 50 years later [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (14) : 1411 - 1412

[9] Immunogenicity in Macaques of the clinical product for a clade B DNA/MVA HIV vaccine:: Elicitation of IFN-γ, IL-2, and TNF-α coproducing CD4 and CD8 T cells [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2007, 23 (12) : 1555 - 1561

[10] Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity [J]. NATURE, 2002, 415 (6869) : 331 - 335